Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings (2 credit hours)

Program Summary:  This course explores the use of medication-assisted treatment and offers guidance for improving the care of individuals with OUD who are or who have been in contact with the criminal justice system.  The course looks at best practices for counseling, medication dosage, medication duration, co-occurring mental health disorders, and post-release services.  FDA-approved medications- methadone, buprenorphine, and naltrexone are discussed.

This course is recommended for social workers, counselors, and therapists and it is appropriate for beginning and intermediate levels of practice 

“Book  Open Chapter One of the Course Reading Here.

“Book  Open Chapter Two of the Course Reading Here.

Reading:  Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings- Overview, Chapter 1, and Chapter 2

Publisher:  US Department of Health and Human Services, SAMHSA

Course Objectives: To enhance professional practice, values, skills, and knowledge by identifying key issues related to medication-assisted treatment in criminal justice settings

Learning Objectives:  Describe barriers for MAT in criminal justice settings.  Identify best practices for MAT in the criminal justice system.  Compare methadone, naltrexone, and buprenorphine.

Review our pre-reading study guide.

In order to purchase or take this course, you will need to log in. If you do not have an account, you will need to register for a free account.

After you log in, a link will appear here that will allow you to purchase this course.

1: For the following questions, please refer to Chapter 1//  The first wave of the opioid epidemic began in the _____________ when prescription opioid overdose deaths began to rise as a result of overprescribing.
 
 
 
 
2: Three generic medications have been approved by the FDA to treat OUDs including all of the following except:
 
 
 
 
3: Naloxone begins to work within
 
 
 
 
4: The average annual cost per person of incarceration in US prisons is @$24,000 versus the per-person cost of methadone maintenance treatment:  ______________.
 
 
 
 
5: Many correctional facilities do not have the ___________ to register as an OTP.
 
 
 
 
6: Which medication does not have demonstrated effects on withdrawal symptoms or cravings?
 
 
 
7: Which medication may only be administered by qualified medical providers in certified OTPs?
 
 
 
8: For the following questions, please refer to Chapter 2//  There is overwhelming evidence that medication assisted treatment is an effective intervention for addressing opioid use disorders in criminal justice and non-criminal justice populations.
 
 
9: Which OUD medication will precipitate withdrawal for persons who have not already been withdrawn from opioids?
 
 
 
10: Significant reductions in mortality have been observed when participants receive methadone or buprenorphine beginning in custody and continuing for at least ___________ consecutive weeks after release to the community.
 
 
 
 
11: When deciding which medication to use in a given case, medical practitioners must consider
 
 
 
 
 
 
 
 
12: Requiring inmates to discontinue or change a medication regimen that was previously successful is associated with
 
 
13: For many individuals, MAT alone may be enough to
 
 
 
14: Evidence is clear that ________-term  treatment with OUD medications is often required for effective and sustained outcomes.
 
 
15: Administering MAT for 90 days or less, which is common practice in many jails and prisons, offers
 
 
 
16: According to the US Surgeon General, successful tapers typically occur, if at all, when individuals have been treated with MAT for at least
 
 
 
 
17: Co-occurring mental health and substance use disorders should be treated
 
 
18: Success after release from custody requires the individual to continue receiving ___________ in the community.
 
 
 
 

In order to purchase or take this course, you will need to log in. If you do not have an account, you will need to register for a free account.

After you log in, a link will appear here that will allow you to purchase this course.

 

Free State Social Work, LLC, provider #1235, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 9/6/2021 - 9/6/2024. Social workers completing this course receive 2 clinical continuing education credits.

Free State Social Work has been approved by NBCC as an Approved Continuing Education Provider, ACEP NO. 6605. Programs that do not qualify for NBCC credit are clearly identified. Free State Social Work is solely responsible for all aspects of the programs.

G.M. Rydberg-Cox, MSW, LSCSW is the Continuing Education Director at Free State Social Work and responsible for the development of this course.  She received her Masters of Social Work in 1996 from the Jane Addams School of Social Work at the University of Illinois-Chicago and she has over 20 years of experience.  She has lived and worked as a social worker in Chicago, Boston, and Kansas City.  She currently practices in the area of hospital/medical social work.  The reading materials for this course were developed by another organization.

If you are interested reading the entire HHS report, you can access it at https://www.freestatesocialwork.com/articles/guide_4-0712_final_-_section_508_compliant.pdf

 

Course Created: August 27, 2019
Filed under: Addiction, Clinical, Opioids